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Introduction: This retrospective study was performed to evaluate
the radiologic features, staging, and resectability of lung cancer at
the time of presentation in patients from the Western Cape of South
Africa.
Method: We included all patients with primary lung cancer re-
viewed during a 12-month period (January 2009 to December 2009)
who had a definite tissue diagnosis and whose staging computed
tomography scans were available. Fifteen radiologic parameters
were assessed.
Results: Data were complete in 204 patients. The proportion and
median size of the various histologic subtypes were as follows:
adenocarcinoma 53.9%, 53.4 mm; squamous cell 25.9%, 80.2 mm;
small cell 14.2%, 80.8 mm; large cell 2.4%, 74.2 mm; bronchioloal-
veolar carcinoma 1.5%, 50.0 mm; and others 2%, 57.6 mm, respec-
tively. The overall median size of tumor was 61.5 mm. Tumors were
located centrally in 43.6%, peripherally in 46.6%, indeterminate in
9.8%, mediastinal in 11.3%, right lung in 53.4%, and in the left lung
in 35.3%. Tuberculosis-related lung fibrosis was present in 16%, but
only 5.4% patients had coexisting tumor and fibrosis at the same
site. We observed no difference in the proportion of coexisting
fibrosis between adenocarcinoma and squamous carcinoma. Only
16.2% of the patients were potential candidates for radical treatment,
with an actual resection rate of 4.4%.
Conclusions: In the Western Cape, adenocarcinoma is the common-
est histologic subtype of bronchogenic carcinoma. Most patients
present with late-stage primary tumors, and the percentage of pa-
tients with potentially resectable cancer is much lower than in
Europe.
Key Words: Radiology features, Histologic subtypes, Lung cancer,
Resection, Africa.
(J Thorac Oncol. 2011;6: 343–350)
Lung cancer remains the most frequent globally diagnosedcancer.1 Several subtypes exist according to the World
Health Organization histologic classification of lung tumors.2
The commonest subtypes currently in Europe and the United
States are adenocarcinoma (50–60%), squamous cell carci-
nomas comprising (30–45%), small cell carcinoma (25%),
large cell carcinoma (5%), and bronchioloalveolar carcinoma
(BAC) (2%).3 Other subtypes include adenosquamous carci-
noma (2%), sarcomatoid carcinoma and its subtypes, and
carcinoid tumors (2%).2 Despite the clear trend observed
internationally, and the absence of any published data from
southern Africa, unpublished data from a large academic
hospital in Johannesburg suggested squamous cell carcinoma
as the most frequent histologic subtype accounting for 43.8%,
with adenocarcinoma, small cell carcinoma, large cell carci-
noma, and others accounting for 21.5%, 16.6%, 8.7%, and
9.4%, respectively.
It has been reported that the histologic subtypes have
certain radiologic features, which may be a frequent finding
though not specific. Squamous cell carcinomas, for example,
tend to be larger and centrally located,4 and cavitation is seen
in approximately 80% of cases. On the contrary, adenocarci-
nomas are usually periphery tumors less than 4 cm in size,
cavitate less (4%), and may demonstrate air bronchograms
or bronchiolograms in approximately 65%. Although the
association between lung cancers and fibrotic lung disease
including tuberculosis is well known,4–6 the pathogenesis of
lung cancer in this setting has yet to be elucidated. One
autopsy study found that less than 25% of scar carcinomas
were related to tuberculosis scars.7 There is paucity of recent
data on the proportion of various histologic subtypes of
primary lung cancer in Africa and no published studies on the
radiologic features and operability at the time of presentation.
We, therefore, aimed to describe these features in patients
from the Western Cape of South Africa.
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Our primary aims were to describe the relative propor-
tions of the various subtypes of primary lung cancer in the
Western Cape of South Africa and to describe the radiologic
features of various primary lung cancer histologic subtypes,
specifically describing tumor location (central or peripheral),
size, presence of cavitation, air bronchogram, fibrosis, pleural
effusion, lymph node involvement, and metastases. The sec-
ondary objective was to review the final clinical staging with
emphasis on the resection rate of lung cancer in this study
population group.
METHODS
Study Population
The medical records of all patients discussed in the
Tygerberg Academic Hospital’s weekly multidisciplinary
thoracic oncology meeting during the period from January 1,
2009, to December 31, 2009, were reviewed for completeness
with respect to tissue diagnosis and a staging computed
tomography (CT) scan. Tygerberg Academic Hospital is a
1200-bed hospital in Cape Town, South Africa. It is one of
the two tertiary centers in the city serving a population of
approximately 1.5 million. This population comprises mostly
people of mixed ethnicity (52.3%), black Africans (27.9%),
and whites (18.2%), and the reported incidence of tubercu-
losis is 940 cases per 100, 000 population.8 Staging CT scans
are routinely performed on all patients with suspected bron-
chogenic carcinoma, either at our institution or at the refer-
ring district or private hospitals in Cape Town and the
surrounding areas in the Western Cape.
Only primary lung cancer cases with clearly defined
histologic subtypes and available CT scans were included in
the study. Patients were excluded if they had pleural malig-
nancy such as mesothelioma or secondary pulmonary malig-
nancies, if their radiology films could not retrieved, and if the
histologic subtypes were not clearly defined. The Stellen-
bosch University Human Research Ethics Committee ap-
proved the study (Study Number N10/01/007).
Radiologic Parameters
Fifteen radiologic parameters were assessed. These
included tumor size, whether the tumor was a solitary pul-
monary nodule (defined as 3 cm in diameter), general
tumor location (central, peripheral, or indeterminate), specific
tumor location (right or left lung or mediastinal), associated
lung collapse, necrosis, cavitation or air bronchograms, co-
existing fibrosis at tumor site, associated pleural effusion,
pleural effusion size, lymph node involvement, metastasis,
organ involvement in metastasis, and staging.
To define location as central or peripheral, we used the
definition suggested by Brooks et al.9 and defined central
tumors as those with the center of the tumor mass within the
hilar structures and peripheral tumors as those where the
center of the mass was within the parenchyma and with no or
minimal contact with the hilar structures. Where the tumor
location could not be accurately defined, this was classified as
indeterminate location. The definition of lymph node involve-
ment was based on lymph node size as seen on the CT scan
and not on pathologic involvement. We defined lymph nodes
measuring 10 mm or more (short axis) as enlarged. Further-
more, we assessed what proportion of these enlarged lymph
nodes were greater than 30 mm and arbitrarily defined these
as massive. Atypical and typical carcinoid tumors were clas-
sified under neuroendocrine tumors, separate from small cell
carcinoma. The size of the tumor was the longest diameter
measured. The presence of an associated pleural effusion was
based on radiologic detection; these effusions were routinely
sampled for cytologic confirmation of malignancy if deemed
necessary. Other information retrieved included the patients’
smoking history, Eastern Cooperative Oncology Group
(ECOG) performance status,10 and how many patients actu-
ally underwent radical surgical treatment.
Histology
Diagnoses of tissue subtypes were based on cyto-
logic or histologic examination, supplemented by ancillary
immunochemistry techniques in most cases. For purposes
of simplicity, we have used the term histologic subtypes in
our discussion regardless of the method used for the final
diagnosis.
Staging, Operability, and Resectability
All cases of bronchogenic carcinoma were staged ra-
diologically according to the sixth edition of International
Union Against Cancer, Tumor, Node, Metastasis Classifica-
tion staging system.11 Although the seventh edition of the
staging system was finally published in July 2009,12 it was
only generally applied to cases of non-small cell lung cancer
(NSCLC) at our institution from September 2009. Therefore,
we decided to apply the sixth edition uniformly for the
purpose of the study, as two thirds of our patients had been
staged using this edition. Lymph nodes were generally staged
radiologically using CT scan, unless operability depended on
it, in which case transbronchial needle aspiration (TBNA)
and mediastinoscopy were routinely performed. Assessment
for metastatic disease in the abdominal organs and vertebral
bodies was based on available staging CT scan films only.
Brain metastases were assessed using brain CT scans for
those in whom they were clinically indicated (we do not
perform CT brain scans as part of routine staging of patients
with lung cancer). Furthermore, routine bone scan or mag-
netic resonance images were not requested. All patients with
potentially operable disease underwent integrated positron
emission tomography and CT scan (PET-CT scan). Our
institution does not yet have endobronchial ultrasound equip-
ment. Therefore, lymph nodes that were suspicious of metas-
tases on PET-CT scanning were sampled using conventional
TBNA combined with rapid onsite evaluation. Mediastinos-
copy was considered for lymph nodes not accessible by or
negative on TBNA. Patients with stages I to IIB were gen-
erally considered to have resectable disease at the onset,
whereas neoadjuvant therapy was generally offered to those
with stage IIIA disease. The final assessment and decision on
operability was made by the multidisciplinary team (includ-
ing respiratory physicians, thoracic surgeons, and oncolo-
gists) based on published guidelines.13
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Statistics
Simple descriptive statistics were calculated using Ex-
cel 2003. Age had a normal distribution, and therefore, mean
and standard deviation values are given. Nevertheless, size of
tumor had a nonnormal distribution, and therefore, the me-
dian was used.
RESULTS
Study Population
During this 12-month period, 302 patients had primary
lung cancer, but only 204 patients fulfilled the inclusion
criteria with available CT scans and clearly defined histologic
subtypes. Ninety-eight patients were excluded (Figure 1). Of
the 40 patients excluded due to the histologic subtype not
being specified, three were potential surgical candidates and
had received radical radiotherapy rather than surgical resec-
tion. The demographics of the included population and the
frequency of the histologic subtypes are summarized in Table
1. Among the 204 patients, data were incomplete in 21% of
the population for smoking history and ECOG performance
status. The mean age was 60.5 years with a male preponder-
ance. Of the 161 patients with complete data on smoking and
performance status, 65% had an ECOG performance status
less than 3, and the mean smoking pack-years was 30.2.
Prevalence and Size
The histologic subtypes are presented in Table 1. Ad-
enocarcinoma was the most prevalent histologic subtype
(53.9%) followed by squamous cell carcinoma, small cell
carcinoma, large cell carcinoma, and BAC. The rest of the
histologic subtypes comprised 4% of the tumors. Table 2
presents the radiologic features of the histologic subtypes.
The overall median size of the tumors in this population was
61.5 mm. The largest tumors were squamous cell carcinoma
and small cell carcinoma. Only nine tumors were solitary
pulmonary nodules.
Location
Overall, 95 (46.6%) and 89 (43.6%) tumors were pe-
ripherally and centrally located, respectively. In 20 patients,
the location was indeterminate. Of the 109 adenocarcinomas,
58.7% were located peripherally, and only 33% were central.
All BACs were peripherally located. In contrast, most squa-
mous cell tumors and approximately 80% of small cell
carcinomas were centrally located. In terms of specific loca-
tion, the right lung had a higher predominance of tumors
(53.4%) compared with the left lung (35.3%), with 11.3%
being mediastinal tumors. In terms of lobar distribution, the
upper lobes were the frequent sites of most tumors in both
lungs. All the histologic subtypes predominantly affected the
upper lobes bilaterally, followed by the lower lobes. In this
population, all lesions located in the lingular were found to be
adenocarcinoma. Middle lobe lesions were predominantly
adenocarcinoma.
Lung Collapse
Out of 204 patients, 61 patients had associated lung
collapse. Twenty-two percent of all patients had partial lobar
302
Lung cancer patients 
204
Included 
98 
Excluded 
52 
No CT scan available 
40 
 Histological subtype not specified 
3
Malignant mesothelioma 
3
Secondary metastases to lungs FIGURE 1. Study population.
TABLE 1. Demographics and Histologic Subtypes for All
Patients (n  204)
Variables Number (%)
Mean age SD (yr) 60.5 SD, 10.6
Sex: male 129 (63.2)
ECOG performance status
0 4 (1.9)
1 58 (28.4)
2 44 (21.6)
3 40 (19.6)
4 15 (7.4)
No data 43 (21.1)
Smokers 151 (74.0)
Nonsmokers 10 (4.9)
No data 43 (21.1)
Pack-years (mean) SD 30.2 SD, 17.8
Histology subtypes
Adenocarcinoma 109 (53.9)
Squamous cell 53 (25.9)
Small cell 29 (14.2)
Large cell 5 (2.4)
Bronchioloalveolar 4 (1.5)
Pleomorphic 2 (1.0)
Neuroendocrine 2 (1.0)
ECOG, Eastern Cooperative Oncology Group.
Journal of Thoracic Oncology • Volume 6, Number 2, February 2011 Radiologic Features, Staging, and Operability
Copyright © 2011 by the International Association for the Study of Lung Cancer 345
TABLE 2. Radiologic Features by Histology Subtype
Radiologic Features
Total
(n  204)
(%)
Adenocarcinoma
(n  109)
Squamous Cell
Carcinoma
(n  53)
Small Cell
(n  29)
Large Cell
(n  5)
BAC
(n  4)
PM
(n  2)
NE
(n  2)
1. Size (median) mm 61.5 53.4 80.2 80.8 74.2 50.0 a a
2. SPN 9 (4.4) 4 (3.7) 3 (5.7) 1 (3.5) 1 (20.0) 0 0 0
3. General location
Central 89 (43.6) 36 (33.0) 27 (50.9) 23 (79.3) 1 (20.0) 0 0 2 (100.0)
Periphery 95 (46.6) 64 (58.7) 19 (35.9) 5 (17.2) 2 (40.0) 4 (100.0) 1 (50.0) 0
Indeterminate 20 (9.8) 9 (8.3) 7 (13.2) 1 (3.5) 2 (40.0) 0 1 (50.0) 0
4. Specific location
Mediastinal 23 (11.3) 4 (3.7) 1 (2.0) 17 (58.6) 0 0 0 1 (50.0)
Right lung
Upper lobe 60 (29.4) 37 (33.9) 13 (24.5) 5 (17.2) 2 (40.0) 0 2 (100.0) 1 (50.0)
Middle lobe 8 (3.9) 5 (4.6) 2 (3.7) 1 (3.5) 0 0 0 0
Lower lobe 32 (15.7) 17 (15.6) 11 (20.8) 1 (3.5) 1 (20.0) 2 (50.0) 0 0
Bronchus intermedius 5 (2.4) 4 (3.7) 1 (2.0) 0 0 0 0 0
Main bronchus 4 (1.9) 4 (3.7) 0 0 0 0 0 0
Total 109 (53.4) 67 (61.5) 27 (51.0) 7 (24.2) 3 (60.0) 2 (50.0) 2 (100.0) 1 (50.0)
Left lung
Upper lobe 50 (24.5) 28 (25.6) 17 (32.1) 3 (10.3) 1 (20.0) 1 (25.0) 0 0
Lingular 2 (1.0) 2 (1.8) 0 0 0 0 0 0
Lower lobe 13 (6.3) 6 (5.5) 5 (9.4) 0 1 (20.0) 1 (25.0) 0 0
Main bronchus 7 (3.4) 2 (1.8) 3 (5.7) 2 (6.8) 0 0 0 0
Total 72 (35.3) 38 (34.8) 25 (47.0) 5 (17.2) 2 (40.0) 2 (50.0) 0 0
5. Lung collapse
Partial 45 (22.1) 20 (18.3) 20 (37.7) 4 (13.9) 0 0 0 1 (50.0)
Complete 16 (7.8) 9 (8.2) 3 (5.7) 3 (10.3) 1 (20.0) 0 0 0
Total 61 (30.0) 29 (26.6) 23 (43.4) 7 (24.2) 1 (20.0) 0 0 1 (50.0)
6. Necrosis 98 (48.0) 45 (41.2) 42 (79.2) 7 (24.2) 3 (60.0) 0 0 1 (50.0)
7. Cavitation 29 (14.2) 11 (10.1) 18 (34.0) 0 0 0 0 0
8. Air bronchograms 13 (6.4) 7 (6.4) 3 (5.7) 0 0 3 (75.0) 0 0
9. Fibrosis
At tumor site 11 (5.4) 5 (4.6) 5 (9.4) 1 (3.5) 0 0 0 0
Other site 22 (10.7) 11 (10.1) 7 (13.2) 2 (6.8) 1 (20.0) 1 (25.0) 0 0
Total 33 (16.1) 16 (14.7) 12 (22.6) 3 (10.3) 1 (20.0) 1 (25.0) 0 0
10. Pleural effusion
Right 23 (11.2) 13 (11.9) 5 (9.4) 4 (13.8) 0 0 0 1 (50.0)
Left 31 (15.2) 17 (15.6) 7 (13.2) 6 (20.6) 1 (20.0) 0 0 0
Bilateral 4 (2.0) 2 (1.8) 2 (3.8) 0 0 0 0 0
Total 58 (28.4) 32 (29.3) 14 (26.4) 10 (34.4) 1 (20.0) 0 0 1 (50.0)
11. Effusion size
Small 42 (20.6) 21 (19.3) 12 (22.6) 9 (31.0) 0 0 0 0
Moderate 59 (2.4) 3 (2.8) 1 (2.0) 1 (3.4) 0 0 0 0
Large 11 (5.3) 8 (7.3) 1 (2.0) 0 1 (20.0) 0 0 1 (50.0)
12. Lymph nodesb
Right hilar (N1) 79 (38.7) 42 (38.5) 26 (49.1) 7 (24.1) 2 (40.0) 0 1 (50.0) 1 (50.0)
Left hilar (N1) 27 (13.2) 13 (11.9) 10 (18.9) 3 (10.3) 0 0 0 0
Bilateral (N3) 71 (34.8) 32 (29.3) 16 (30.1) 20 (69.0) 1 (20.0) 0 1 (50.0) 1 (50.0)
Subcarinal (St 7, N2) 124 (60.8) 64 (58.7) 31 (58.4) 24 (82.8) 2 (40.0) 0 1 (50.0) 1 (50.0)
Otherc 150 (73.5) 82 (75.2) 37 (69.8) 25 (86.2) 4 (80.0) 0 2 (100.0) 0
Massive (3.0 cm) 56 (27.4) 25 (22.9) 11 (20.8) 17 (58.6) 1 (20.0) 0 1 (50.0) 1 (50.0)
13. Metastasis
Yes 130 (63.7) 74 (67.9) 27 (50.9) 23 (79.3) 2 (40.0) 2 (50.0) 1 (50.0) 1 (50.0)
No 74 (36.3) 35 (32.1) 26 (49.1 6 (20.7) 3 (60.0) 2 (50.0) 1 (50.0) 1 (50.0)
(Continued)
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or segmental collapse and 7.8% had complete collapse of the
whole lung. There was no difference in the number of
patients with partial collapse between adenocarcinoma (n 
20) and squamous cell carcinoma. Adenocarcinoma contrib-
uted to most of the completely collapsed lungs. Only one of
the large cell carcinomas had associated complete collapse.
Necrosis, Cavitation, and Air Bronchograms
Most of the squamous cell and large cell tumors
showed radiologic and pathologic evidence of necrosis (79%
and 60%, respectively) compared with 41% of adenocarci-
nomas and 24% of small cell carcinomas. Compared with
the proportion of necrosis, cavitation was only evident in a
smaller proportion of squamous cell tumors and adenocar-
cinomas with none in the large cell tumors. Air bron-
chograms were observed in 75% of the BACs and 6.4% of
the adenocarcinomas.
Fibrosis and Pleural Effusions
Thirty three patients (16.1%) had coexisting tuberculo-
sis-related lung fibrosis and lung cancer. Only 11 patients had
fibrosis and lung tumor at the same site, of which adenocar-
cinoma and squamous cell carcinoma had equal proportions
(n  5) and one was small cell carcinoma. Pleural effusions
were found in 58 patients. Among the histologic subtypes,
adenocarcinoma was associated with most of the effusions
(n  32, 29% of all patients with adenocarcinoma) with only
one effusion associated with large cell tumors.
Lymph Node Involvement and Size
Among the 204 patients, there were 451 lymph nodes
involved as defined above of which 61% were subcarinal and
74% involved other mediastinal nodes. Left hilar nodes were
less involved compared with right hilar nodes (13% versus
38%, respectively). Squamous cell carcinoma had a greater
right hilar nodal involvement than either adenocarcinoma or
small cell carcinoma. The proportion of left hilar nodal
involvement in each of the three major histologic subgroups
was almost equal. Small cell carcinoma had the highest
proportion of bilateral hilar, subcarinal, and other mediastinal
nodal involvement. Massive lymphadenopathy (3 cm) was
seen in 27% of all patients and was most notable in small cell
carcinoma.
Metastasis and Organ Involvement
Overall, 130 patients had metastatic deposits. Metasta-
ses were observed in 79% of all small cell carcinomas
compared with 68% and 51% of adenocarcinoma and squa-
mous cell carcinoma, respectively. Two of the large cell
carcinomas had metastases. Pulmonary nodules other than the
primary tumor were noted in 37% of the patients. Involve-
ment of liver, adrenals, and vertebral bones comprised 35%,
whereas the brain was involved in approximately 7.5%. Small
cell carcinomas had a higher proportion of coexisting pulmo-
nary nodules (66%) compared with the other histologic sub-
types. Adenocarcinoma and small cell carcinoma had an
almost similar proportion of metastasis to the brain (10%)
and to the other organs (39.5% and 37.9%, respectively). In
the two BACs with spread to other organs, one involved the
lung and the other involved the brain and liver.
Staging and Operability
A total of 160 patients (78%) with NSCLC had inop-
erable primary lung cancer at the time of the staging CT
imaging (stage 3A–stage IV NSCLC) (Table 2). Seventy-nine
TABLE 2. (Continued)
Radiologic Features
Total
(n  204)
(%)
Adenocarcinoma
(n  109)
Squamous Cell
Carcinoma
(n  53)
Small Cell
(n  29)
Large Cell
(n  5)
BAC
(n  4)
PM
(n  2)
NE
(n  2)
14. Organ involvementd
Pulmonarye 74 (36.8) 41 (37.6) 18 (34.0) 14 (65.5) 0 1 (25.0) 1 (50.0) 0
Brain 15 (7.4) 10 (9.2) 1 (2.0) 3 (10.3) 0 1 (25.0) 0 0
Other 72 (35.3) 43 (39.5) 14 (26.4) 11 (37.9) 2 (40.0) 1 (25.0) 0 1 (50.0)
Total 161 (78.9) 94 (86.2) 33 (62.2) 28 (96.6) 2 (40.0) 3 (75.0) 1 (50.0) 1 (50.0)
15. Staging
IA 3 (1.5) 0 2 (3.8) n/a 0 1 (25.0) 0 n/a
IB 7 (3.4) 3 (2.8) 3 (5.7) n/a 0 1 (25.0) 0 n/a
IIA 0 0 0 n/a 0 0 0 n/a
IIB 3 (1.5) 3 (2.8) 0 n/a 0 0 0 n/a
IIIA 12 (5.8) 8 (7.3) 3 (5.7) n/a 1 (20.0) 0 0 n/a
IIIB 42 (20.6) 21 (19.3) 18 (34.0) n/a 2 (40.0) 0 1 (50.0) n/a
IV 106 (52.0) 74 (67.8) 27 (50.8) n/a 2 (40.0) 2 (50.0) 1 (50.0) n/a
Limited 7 (3.40 6 (20.7) 1 (50.0)
Extensive 24 (11.8) 23 (79.4) 1 (50.0)
a PM sizes 81.2 and 56.2 mm: NE size 35.4 mm. One NE was mediastinal and unable to measure size.
b Total lymph node is 204, as one patient can have involvement of several lymph node stations, e.g., right hilar, subcarinal, and aorto-pulmonary window.
c Other lymph nodes: retrocaval, precarinal, pretracheal, or aorto-pulmonary window nodes.
d A patient could have spread to more than one organ.
e Pulmonary means either ipsilateral or contralateral or both. In old staging, ipsilateral lung involvement was T4 and, therefore, not metastasis.
BAC, bronchioloalveolar carcinoma; PM, pleomorphic; NE, neuroendocrine, SPN, solitary pulmonary nodule; n/a, non-applicable.
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percentage of all small cell carcinomas had extensive disease.
During this 12-month period, 33 of 204 patients with lung
cancer (16.2%) who were potential candidates for radical
treatment, based on CT scan staging, underwent PET-CT
scans. After PET-CT scanning, 19 patients were up-staged
and no longer considered as candidates for surgical treatment
due to positive extrathoracic N3 disease on PET-CT scan
(three patients), positive N2 disease on TBNAs (four pa-
tients), presence of metastatic disease (11 patients), and one
patient with confirmed adenocarcinoma restaged as T4 but
with nodal granulomatous disease on mediastinoscopy. We
did not retrieve the treatment data on these patients. Only 14
patients (6.9%) were candidates for resection after PET-CT
scanning. Of these 14 patients, nine patients eventually had
their tumors surgically removed, comprising 4.4% of all the
patients with cancer studied during the 12-month study pe-
riod. Five of the 14 patients did not have surgery but radical
radiotherapy as appropriate. In three of these patients, N1
disease was confirmed on TBNA (two patients) and medias-
tinoscopy (one patient). Of the other two patients, one had
stage IB squamous cell carcinoma and opted for radical
radiotherapy, whereas one had BAC and was treated with
chemotherapy.
DISCUSSION
In this study population with primary lung cancer, we
found adenocarcinoma to be the commonest histologic sub-
type. Most patients had advanced disease at presentation with
only 4.4% finally undergoing treatment by surgical resection.
Furthermore, in a population with an extremely high inci-
dence of tuberculous lung disease, we observed little evi-
dence of coexisting tumor and tuberculosis-related fibrosis at
the same site. In general, most tumors were located in the
right lung, with a predilection for the upper lobe. Our data
provide the first convincing evidence from South Africa that
adenocarcinoma has overtaken squamous cell carcinoma as
the most frequently diagnosed subtype of primary lung can-
cer. Contrary to previous reports, we diagnosed 54% of lung
cancers were adenocarcinomas, whereas only 26% were
squamous carcinomas.
It is interesting to note that South Africa lagged behind
with the shift from squamous cell carcinoma to adenocarci-
noma. Although the lack of recent published epidemiological
data may be in part to blame for this apparent phenomenon,
the likely explanation for the current shift is presumably the
same as suggested for Europe and the United States. Factors
that have been implicated for the shift include a decrease in
average nicotine and tar delivery of cigarettes, the composi-
tion of cigarette tobacco blend, and the use of filter tips.4,14
The predilection of bronchogenic carcinoma for the
right lung and upper lobes has been documented by previous
authors.15–18 As far back as the 1960s, Garland15 in a series of
250 patients showed that most bronchogenic carcinomas
affect the right lung more than the left lung (53% versus 44%)
with a predilection for the upper lobes. Theros16 found 60%
of bronchogenic tumors located in the right lung with 60%
affecting both upper lobes, 30% in the lower lobes, and 10%
in middle lobes. Byers et al.17 found 65% of primary lung
cancers affecting the upper lobes with only 28% affecting the
lower lobes. In our study, 53% of the tumors were in the right
lung compared with 35% in the left lung, with 55% affecting
both upper lobes and only 22% affecting the lower lobes.
Byrd et al. studied radiographic features of the four
major histologic cell types in 600 patients with bronchogenic
carcinoma. They found 72% of cases of adenocarcinoma
were located peripherally, 63% for large cell carcinoma, 31%
for squamous cell carcinoma, and 32% for small cell carci-
noma.18 In our study, with the exception of squamous cell
carcinoma, the proportions are lower for the other cell types
being found in the periphery compared with the results of
Byrd et al. Consistent with our finding, it has been stated that
33% of squamous cell carcinomas are located peripherally.19
Lung collapse and obstructive pneumonitis were found in
53% squamous cell, 25% adenocarcinoma, 10% large cell,
and 13% of small cell carcinoma in the study by Byrd et al.,18
whereas pleural effusions were present in 3%, 5%, 2%, and
5% of the cell types, respectively. We also found a higher
proportion of lung collapse in squamous cell carcinoma and
a similar higher proportion of pleural effusions in adenocar-
cinoma and small cell carcinoma.
In contrast to the findings of Bryd et al., Quinn et al.20
observed 25 years later an increase in prevalence of adeno-
carcinoma, with 45% of this cell type being a peripheral
mass. The proportion of peripheral squamous cell, small cell,
and large cell tumors were 39%, 34%, and 68%, respectively.
Pleural effusions were found in 20% adenocarcinoma, 23%
squamous cell, 30% small cell, and 14% of large cell tumors,
whereas obstruction/collapse was found in 29%, 43% 50%,
and 27%, respectively.
With respect to size, our study shows an average size of
61.5 mm for all tumors, with the largest cell types being
squamous, small cell, and large cell (70 mm). In contrast to
our study, a North American study of 1267 lung neoplasms,
of which only 714 could be evaluated for size, found the
average tumor size of 5 cm or less.16 In our study, even the
slow-growing BAC had a larger average size.
It has been reported that squamous cell carcinoma is the
most common cell type to cavitate.16,18,21 In the study by
Byrd et al., cavitation was found in 22% of squamous cell
cancer, 2% of adenocarcinoma, 6% of large cell carcinoma,
and none in BAC or small cell carcinoma. Theros16 observed
cavitation in 12% of peripheral squamous and in approxi-
mately 6% of each of adenocarcinoma and BAC, with none in
small cell carcinoma. We found a much higher proportion of
necrosis and cavitation in the squamous cell type. This higher
proportion of cavitation could again be attributed to progres-
sive growth of disease only detected late, compared with
patients with lung cancer in the western countries who
present early with smaller sized tumors.
Most of our patients had radiologic evidence of apical
tuberculosis-related fibrosis. Although the association of lung
cancer in fibrotic lung disease including tuberculosis has been
established,6,7,22–26 there is still some debate on the etiology
of fibrosis-related carcinoma. It has been suggested that
fibrosis may occur as a desmoplastic reaction to an already
existing carcinoma similar to that occurring in breast carci-
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noma.27–30 On the other hand, it has recently been shown in
experimental studies that chronic tuberculosis infection in-
duces cell dysplasia and squamous cell carcinoma in a lung-
specific way.31 In a retrospective autopsy study of 82 lung
cancer cases associated with a scar, Auerbach et al.7 docu-
mented 23% being associated with tuberculosis. In terms of
the association of scar carcinomas and specific histologic
subtypes, Auerbach et al. found 59 cases of scar carcinomas
were adenocarcinomas, 15 were squamous cell, and eight
were large cell carcinomas, out of 82 scar cancers. Theros16
found scar-associated cancer in five squamous cell carcino-
mas, five adenocarcinomas, and interestingly in 17 BAC,
with no scar-associated cancer in the rest of the cell types.
Nonetheless, our findings are consistent with the aforemen-
tioned authors in terms of lower proportions of coexisting
lung cancer with tuberculosis-related fibrosis.
We found a very low proportion of patients with po-
tentially operable lung cancer at presentation (16.2%) with
only nine patients (4.4%) actually undergoing surgical resec-
tion of their tumors. In the 2009 U.K. national lung cancer
audit, the overall unadjusted proportion of patients who
received surgical operations was approximately 11%, with
regional variations ranging from less than 5% to more than
25%.32 Our findings do compare with some regions in the
United Kingdom. The proportion of patients undergoing
resection in our study was, however, much lower than that
observed in other European countries such as Italy 24%,33
Sweden 17.5%,34 and Netherlands 20%.35 Although the U.K.
national audit attributed the lower resection rates to reduced
access to specialist thoracic surgeons, we attribute this lower
proportion of operable cases in our study to the late presen-
tation by patients to the specialist clinics, resulting in clini-
cally advanced tumors. We postulate that in a region with a
high incidence of tuberculosis (940/100,000),8 tuberculosis is
a confounding problem, simulating some of the radiologic
features and symptoms of lung cancer. Primary health care
workers in the community hospitals and clinics may, there-
fore, initially investigate and treat for pulmonary tuberculo-
sis, only referring patients to the specialist lung clinics when
there is no clinical or radiologic improvement. Data from
Korea revealed an average delay of 11.7 months in diagnos-
ing lung cancer due to masking of new lesions by coexisting
stable tuberculosis lesions, misinterpretation of new nodules
as aggravation of tuberculosis, misinterpretation of lung can-
cer as tuberculoma at initial radiography, masking of nodule
by an active tuberculous lesion, and subtleness of the lesion.36
Besides the confounding factor due to tuberculosis, ethnic
and socioeconomic factors contribute to the late presentation
of patients with lung cancer. For example, it is common for
patients to first seek medical treatment from traditional heal-
ers or for patients to fail to attend clinic appointments for fear
of loss of employment and income. Transport costs to and
from the hospital may further deter some patients from
presenting early to hospitals.
The strength of our study was the use of CT scans to
review the lung tumors. Most previous studies on radiopatho-
logical features were based on chest radiographs. Our study,
however, has several limitations. First, the size of our sample
population is lower compared with other previous similar
studies. Thirty-two percentage of patients were excluded.
Being a retrospective study, the study was limited by failure
to retrieve CT scan films done at other district general and
private hospitals. Nevertheless, it seems unlikely that the
resection rate would have been higher than 4.4% had we
managed to access all the patients’ records. Second, we have
not reported the various treatment received by those who
were not surgical candidates, as our secondary objective was
on the surgical resection. Third, we used the sixth tumor,
node, metastasis staging system when currently the seventh
edition is in use. Despite these limitations, our study does
provide valuable information on lung cancer in this part of
Africa. To our knowledge, this is the first study of primary
lung cancer in Africa looking at such radiopathologic corre-
lation and surgical resection rates.
In conclusion, adenocarcinoma is the commonest his-
tologic subtype of bronchogenic carcinoma diagnosed in the
Western Cape of South Africa. Patients present with rela-
tively advanced tumors that have radiologic features compa-
rable with those described in western countries, although the
percentage of potentially resectable cancer is much lower
than in Europe. Furthermore, the prevalence of carcinoma
associated with fibrosis was lower than anticipated. There is
an urgent need to engage the public and health care workers
in raising the awareness for lung cancer.
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